Frederico Luiz Dulley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Frederico Luiz Dulley has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
R Saboya
Hematology-BMT Department, University of São Paulo, São Paulo, Brazil
2 shared publicationsRosaura Saboya
Universidade de São Paulo (USP), São Paulo, SP, Brazil
2 shared publicationsA M Júnior
Fundação Pró-Sangue/Hemocentro de São Paulo, São Paulo, Brazil
1 shared publicationAlessandra Barban
Universidade de São Paulo (USP), São Paulo, SP, Brazil
1 shared publicationAndrea Barban
Hospital Inglês, São Paulo, SP, Brazil
1 shared publicationBelinda Simões
USP de Ribeirão Preto, Ribeirão Preto
1 shared publication
Latest Publications
- Open Access
- 29 May 2014
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 36 (4) , 264-268
Analysis of the feasibility of early hospital discharge after autologous hematopoietic stem cell transplantation and the implications to nursing care
- 29 May 2014
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 36 (4) , 264-268
Open AccessAnalysis of the feasibility of early hospital discharge after autologous hematopoietic stem cell transplantation and the implications to nursing care
- Open Access
- 1 May 2010
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 32, 13-15
Transplante de medula óssea com doador familiar parcialmente compatível
- 1 May 2010
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 32, 13-15
Open AccessTransplante de medula óssea com doador familiar parcialmente compatível
- 1 May 2009
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 31, 53-58
Células-tronco hematopoéticas: utilidades e perspectivas
- 1 May 2009
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 31, 53-58
Células-tronco hematopoéticas: utilidades e perspectivas
- 17 November 2008
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 43 (9) , 741-742
Strongyloides stercoralis hyperinfection after allogeneic stem cell transplantation
- 17 November 2008
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 43 (9) , 741-742
Strongyloides stercoralis hyperinfection after allogeneic stem cell transplantation
- Open Access
- 1 August 2008
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 30 (4) , 263-264
Allogeneic bone marrow transplantation for severe aplastic anemia patients with risk factors poor prognosis: is fludarabine a requirement?
- 1 August 2008
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 30 (4) , 263-264
Open AccessAllogeneic bone marrow transplantation for severe aplastic anemia patients with risk factors poor prognosis: is fludarabine a requirement?
- 15 October 2007
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 41 (1) , 95-96
Neurotoxicity associated with dimethylsulfoxide-preserved hematopoietic progenitor cell infusion
- 15 October 2007
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 41 (1) , 95-96
Neurotoxicity associated with dimethylsulfoxide-preserved hematopoietic progenitor cell infusion
- Open Access
- 1 December 2005
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 123 (6) , 266-270
Liposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
Liposomal daunorubicin has been used to treat hematological malignancies, including multiple myeloma (MM). The goal was to evaluate efficacy, side-effects and toxicity of liposomal daunorubicin and dexamethasone ("DD Protocol"). Prospective study at Sírio-Libanês, São Camilo, Brasil and Alemão Oswaldo Cruz hospitals. Twenty consecutive patients with active MM received four cycles of liposomal daunorubicin intravenously for two hours (25-30 mg/m(2)/day) on three consecutive days per month, with oral dexamethasone (10 mg every six hours) on four consecutive days three times a month. The male/female ratio was 1:1 and median age 60. Nine patients were stage IIA, ten IIIA and one IIIB. The median from diagnosis to starting DD was 13 months. All patients received four cycles, except one. Fifteen had already received chemotherapy before DD. Responses of > 50% reduction in serum monoclonal paraprotein were observed in six patients after first cycle (30%), six after second (30%) and four after third (20%), while four (20%) did not obtain this. Initially, 17 patients (85%) had anemia: 12 (70%) achieved correction. Progressive disease was observed in three patients (15%), while one had minimal response, four (20%) partial and 12 (60%) complete. Hematological toxicity was acceptable: three patients (15%) had neutrophils < 1,000/mm(3); none had thrombocytopenia. Gastrointestinal toxicity was mild: nausea (10%), anorexia (15%) and no vomiting. This treatment has mild toxicity and good response rate. It may therefore be feasible before autologous bone marrow transplantation.
- 1 December 2005
- Published by FapUNIFESP (SciELO) in Sao Paulo Medical Journal
- Vol. 123 (6) , 266-270
Open AccessLiposomal daunorubicin and dexamethasone as a treatment for multiple myeloma: the DD Protocol
Liposomal daunorubicin has been used to treat hematological malignancies, including multiple myeloma (MM). The goal was to evaluate efficacy, side-effects and toxicity of liposomal daunorubicin and dexamethasone ("DD Protocol"). Prospective study at Sírio-Libanês, São Camilo, Brasil and Alemão Oswaldo Cruz hospitals. Twenty consecutive patients with active MM received four cycles of liposomal daunorubicin intravenously for two hours (25-30 mg/m(2)/day) on three consecutive days per month, with oral dexamethasone (10 mg every six hours) on four consecutive days three times a month. The male/female ratio was 1:1 and median age 60. Nine patients were stage IIA, ten IIIA and one IIIB. The median from diagnosis to starting DD was 13 months. All patients received four cycles, except one. Fifteen had already received chemotherapy before DD. Responses of > 50% reduction in serum monoclonal paraprotein were observed in six patients after first cycle (30%), six after second (30%) and four after third (20%), while four (20%) did not obtain this. Initially, 17 patients (85%) had anemia: 12 (70%) achieved correction. Progressive disease was observed in three patients (15%), while one had minimal response, four (20%) partial and 12 (60%) complete. Hematological toxicity was acceptable: three patients (15%) had neutrophils < 1,000/mm(3); none had thrombocytopenia. Gastrointestinal toxicity was mild: nausea (10%), anorexia (15%) and no vomiting. This treatment has mild toxicity and good response rate. It may therefore be feasible before autologous bone marrow transplantation.
- Open Access
- 1 March 2005
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 27 (1) , 3
Bussulfano e ciclofosfamida no condicionamento do transplante de medula óssea para anemia aplástica grave
- 1 March 2005
- Published by Elsevier in Revista Brasileira de Ginecologia e Obstetrícia
- Vol. 27 (1) , 3
Open AccessBussulfano e ciclofosfamida no condicionamento do transplante de medula óssea para anemia aplástica grave